Curasight completes DKK 20 million directed share issue
What's the deal? Danish biotech CurasightDealroom has a profile for this one. Try Dealroom → has completed a directed share issue worth roughly DKK 20 million ($3.1 million) before costs.
The company issued 1,120,605 new shares at DKK 17.80 each, drawing Nordic and international institutional investors, both new and existing.
Why now? Curasight reported encouraging interim data from its Phase I uTREAT study in 2026.
The fresh capital will strengthen working capital and fund continued clinical development of its uTRACE and uTREAT candidates through the end of H1 2027.
The share price was set through an accelerated bookbuilding run by Sedermera Corporate Finance, at a 10.28% discount to the recent volume-weighted average price.
What could go wrong? The board chose a directed issue over a rights issue, sidestepping existing shareholders' pre-emption rights.
It argued a rights issue would take longer, cost more, and risk being undersubscribed. The discount and dilution may still frustrate some current holders.
Curasight also renegotiated its outstanding loan from Fenja CapitalDealroom has a profile for this one. Try Dealroom → II as part of the raise.
The signal: Curasight's focus on novel PET imaging ligands for prostate cancer places it among a wave of early-stage diagnostics-led biotechs betting that imaging breakthroughs can guide treatment — its dual uTRACE and uTREAT programmes aim to pair diagnosis with therapy. For an early-stage company, securing institutional backing off the back of interim Phase I data offers a runway through H1 2027 to reach the milestones that matter most.
Read more: MarketScreener
Image credit: "Fully Integrated Whole-body Simultaneous PET/MRI Device" by National Institutes of Health (NIH) is marked with Public Domain Mark 1.0. To view the terms, visit https://creativecommons.org/publicdomain/mark/1.0/.
